Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue.

ir para o conteúdo

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Verificação do setor da saúde

Esta secção contém informações destinadas a profissionais de saúde.

Confirme que faz parte de uma empresa do setor da saúde.

Multiple Myeloma: « 20 » and « 100 » Ratios Cut-off applicable to Sebia FLC assays

The « 20 » and « 100 » Ratios Cut-off are respectively used in routine for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis. This publication shows that such cut-off are applicable to the Sebia FLC assays.

Publicações: 10/11/2026 | Modificado: 10/11/2026

In 2014, the IMWG has added SLiM criteria (bone marrow plasmacytosis ≥ 60%, FLC i/u ≥100 along with the iFLC ≥ 100 mg/L, > 1 focal lesion on MRI) to the CRAB criteria (calcium elevation, renal insufficiency, anemia), as Myeloma Defining Events.

The iFLCr threshold (100) was defined because it was the cut-off associated with a 79% risk of progression to MM (Multiple Myeloma) or AL (AL amyloidosis) within 24 months, and with a specificity of 97% (Larsen JT et al, Leukemia, 2013).

In addition to this 100 ratio, the IMWG has then introduced the 20-20-20 system for assessing the Smoldering Multiple Myeloma (SMM) to MM progression. In that system, a patient with SMM receives 1 risk point for each of the following (M-spike>20 g/L, iFLCr>20 and BMPC>20%). This score is notably used for trial stratification and eligibility.

This publication indicates that the FLC cut-points can be used with Sebia ELISA FLC tests and allow for comparability within the field, to ensure an appropriate patient management.

Comparison-of-two-FLC_Publication

Test associated with this resource

Related instrument

Discover more resources on Multiple Myeloma

Esta secção contém informações destinadas a ampla divulgação e, por conseguinte, pode conter detalhes sobre produtos ou informações que não estejam disponíveis ou não sejam válidas no seu país. Contacte o seu representante local da Sebia. Informações destinadas a profissionais de saúde. Leia atentamente as instruções constantes das bula dos reagentes e dos manuais dos instrumentos.